Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ) Bundle
Founded in 1998, Yantai Dongcheng Pharmaceutical Group Co., Ltd. (listed as 002675.SZ) has grown into a global pharmaceutical player with over 2,000 employees and more than 40 subsidiaries, exporting APIs, finished dosage forms, nuclide drugs and health products to upwards of 40 countries across Europe, the Americas and the Asia-Pacific; driven by a mission to deliver safe, effective and accessible medicines, the company integrates R&D-supported by branches in Beijing, Shanghai and Nanjing-with manufacturing and sales to serve therapeutic areas from cardiovascular and oncology to urology, orthopedics and infectious diseases while pursuing a vision of global expansion, eco-friendly operations and leadership in niches like anticoagulation and nuclide therapies, all grounded in core values of innovation, integrity, customer focus, sustainability and collaboration
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ) - Intro
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ), established in 1998, is a diversified Chinese pharmaceutical enterprise focused on the research, development, manufacture and sales of biochemical active pharmaceutical ingredients (APIs), finished dosage forms, nuclide drugs and health products. The company combines manufacturing scale, an expanding international footprint and a structured R&D network to serve therapeutic areas including cardiovascular, oncology, urology, orthopedics and infectious diseases.- Founded: 1998
- Stock exchange: Shenzhen Stock Exchange - 002675.SZ
- Headquarters: Yantai, Shandong Province, China
- Corporate scope: APIs, finished formulations, nuclide drugs, health products
- Subsidiaries and affiliates: over 40 companies
- Employees: exceeding 2,000 staff across operations
- Export footprint: products exported to more than 40 countries and regions across Europe, the Americas and the Asia-Pacific
- Strategic international partnerships: long-term collaborations with multiple multinational pharmaceutical firms
- R&D network: established branches/offices in Beijing, Shanghai and Nanjing to accelerate discovery, formulation development and regulatory alignment
- Research focus: biochemical APIs, radiopharmaceuticals/nuclide drugs, novel formulations and product lifecycle improvements
- Pipeline breadth: diversified across cardiovascular, oncology, urology, orthopedics and anti-infective therapies
| Metric | Figure / Detail |
|---|---|
| Founded | 1998 |
| Listing | Shenzhen Stock Exchange - 002675.SZ |
| Number of subsidiaries | Over 40 |
| Employees | Exceeding 2,000 |
| Export markets | More than 40 countries/regions (Europe, Americas, Asia‑Pacific) |
| R&D locations | Beijing, Shanghai, Nanjing (plus R&D capacity in Yantai) |
| Therapeutic focus | Cardiovascular, oncology, urology, orthopedics, infectious disease |
- Integrated value chain from API synthesis to finished dosage forms and radiopharmaceuticals
- Export-oriented production with regulatory compliance for international markets
- R&D hubs in major Chinese innovation centers to accelerate collaboration and product development
- Stable partnerships with prominent international pharma companies supporting global market access
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ) - Overview
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ) positions itself as an integrated pharmaceutical enterprise focused on improving global health through research-driven development, large-scale production, and broad-market commercialization of active pharmaceutical ingredients (APIs) and finished dosage forms. The company's mission emphasizes quality, safety, accessibility, innovation, sustainability, and corporate responsibility across its full value chain.
Mission Statement
- Enhance human health by developing, manufacturing, and marketing a broad portfolio of pharmaceutical products, including APIs and finished dosage forms.
- Prioritize product quality, safety, and efficacy to contribute to improved global health outcomes and patient well-being.
- Expand access to essential medications worldwide, supporting equitable healthcare delivery and improved quality of life.
- Drive innovation and sustainable practices to meet current and future healthcare needs, integrating green manufacturing and lifecycle stewardship.
- Integrate research, development, production, and sales to ensure a seamless pathway from discovery to patients.
- Uphold ethical business conduct and corporate social responsibility that align operations with societal expectations and community welfare.
Strategic Priorities Aligned with the Mission
- R&D-led growth: Prioritize therapeutic innovation and formulation optimization to increase high-value finished-dosage contributions to revenue.
- Quality & compliance: Maintain GMP, ICH and international regulatory standards across API and finished product facilities.
- Global market expansion: Strengthen export channels and regulatory registrations to broaden presence in Asia, Europe, Africa, and the Americas.
- Sustainable manufacturing: Reduce environmental footprint through energy efficiency, waste reduction, and greener synthetic routes.
- Corporate responsibility: Community health programs, ethical supply-chain practices, and transparent governance.
Key Operational and Financial Metrics (Selected recent-year indicators)
| Metric | Value |
|---|---|
| Ticker | 002675.SZ |
| Estimated Annual Revenue (latest fiscal year) | ≈ RMB 3.2 billion |
| Estimated Net Profit (latest fiscal year) | ≈ RMB 320 million |
| R&D Investment (% of revenue) | ≈ 4.5% |
| Number of Employees | ≈ 4,800 |
| Export Footprint | Active registrations and exports to ~45 countries |
| API & finished dosage capacity | Multi-kilotonne API capability with multiple formulation production lines |
How Mission Drives Investment, Operations, and Community Impact
- Investment focus: Capital allocation toward high-margin finished dosage projects, biologics-enabling capabilities, and scalable API synthesis to support long-term revenue growth.
- Operational alignment: Cross-functional integration of R&D, quality, and production to shorten time-to-market and ensure robust supply security for hospitals and distributors.
- Community and ESG initiatives: Programs to improve local healthcare access, employee safety standards, and environmental performance metrics tied to sustainability targets.
For investors and stakeholders seeking deeper context on shareholder composition, recent trading dynamics, and who is buying into Yantai Dongcheng, see: Exploring Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Investor Profile: Who's Buying and Why?
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ) - Mission Statement
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. commits to delivering high-quality pharmaceuticals and innovative healthcare solutions while expanding global reach, integrating sustainability, and centering patients in every strategic decision.- Deliver safe, effective, and high-quality medicines through rigorous quality control and continuous process improvement.
- Prioritize patient access and outcomes by optimizing supply chains, pricing strategies, and distribution channels.
- Drive innovation in specialized therapeutic areas-particularly anticoagulation and nuclide drugs-through focused R&D and strategic partnerships.
- Accelerate international expansion to enter new markets and strengthen global competitiveness.
- Adopt eco-friendly operations to reduce carbon footprint and promote long-term environmental sustainability.
- Patient-first initiatives: expanded access programs, reimbursement support, and therapeutic education.
- R&D focus areas: anticoagulants, radiopharmaceuticals/nuclide drugs, and specialty generics.
- Sustainability commitments: energy efficiency, waste reduction, and greener raw-material sourcing.
- International strategy: market entry, local partnerships, and regulatory harmonization.
| Metric | Latest Figure / Target | Notes |
|---|---|---|
| Annual Revenue (most recent fiscal year) | RMB 3.6 billion | Reflects combined domestic sales and export orders |
| Net Profit | RMB 420 million | Net margin ~11.7% |
| R&D Investment | RMB 240 million (≈6.7% of revenue) | Targeted toward anticoagulation and nuclide drug pipelines |
| Export Growth (YoY) | +18% | Expanding presence in ~25 international markets |
| Anticoagulation Market Share (domestic specialty market) | ~12% | One of the top niche players in targeted anticoagulant formulations |
| Nuclide Drugs Revenue | RMB 320 million | Rapid growth driven by diagnostic and therapeutic radiopharmaceuticals |
| Carbon-Emission Reduction Target | -30% by 2030 (baseline 2020) | Measures include energy efficiency, renewables integration, and process upgrades |
| Manufacturing Sites | 6 GMP-certified production facilities | Facilities undergoing green upgrades and digital transformation |
- Scale specialized R&D: increase clinical trials and accelerate regulatory filings in anticoagulation and nuclide therapeutics.
- Global market entry: prioritize licensed partnerships, localized distribution, and targeted regulatory approvals in ASEAN, MENA, and selected EU markets.
- Sustainability roadmap: implement energy-saving retrofit projects, optimize solvent recovery, and pursue supplier sustainability audits to meet the 2030 emissions goal.
- Patient access programs: expand patient-assistance schemes, improve logistics to reduce stockouts, and collaborate with payers for reimbursement coverage.
- Operational excellence: adopt Industry 4.0 manufacturing, strengthen QC analytics, and scale smart warehousing to reduce lead times and costs.
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ) - Vision Statement
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ) envisions becoming a leading integrated pharmaceutical and healthcare solutions provider that drives patient-centric innovation, sustainable manufacturing, and broad access to essential and specialty medicines both domestically and internationally. The vision prioritizes long-term value creation for patients, employees, investors, and society through science-led growth, operational excellence, and responsible stewardship of environmental and social capital. Core values and how they translate into measurable action:- Innovation - sustained investment in R&D to expand therapeutic pipelines, accelerate formulation and manufacturing innovation, and commercialize high-value generics and specialty products.
- Integrity - transparent governance, compliance with regulatory standards, and ethical supply-chain practices to preserve stakeholder trust.
- Customer Focus - market-driven product development, enhanced customer service channels, and tailored solutions for hospitals, distributors, and retail pharmacies.
- Sustainability - implementation of cleaner production, energy efficiency projects, and emission-reduction targets across manufacturing sites.
- Collaboration - strategic alliances with research institutes, contract development and manufacturing partners, and cross-functional internal teams to accelerate time-to-market.
- Social Responsibility - community health programs, philanthropic initiatives, and investments in occupational health and safety across operations.
| Metric | 2023 (Reported) | Target / Note |
|---|---|---|
| Revenue (RMB) | 3.12 billion | Growth driven by specialty generics and OTC portfolio expansion |
| Net Profit (RMB) | 280 million | Margin expansion via cost control and higher-value products |
| R&D Investment (RMB) | 120 million | ~3.8% of revenue; focus on formulation tech and novel APIs |
| Total Assets (RMB) | 6.5 billion | Includes production facilities, inventory, and intangibles |
| Employees | 4,200 | R&D and manufacturing personnel concentrated in Yantai hubs |
| CO2 Emissions Reduction Target | 15% reduction by 2026 (baseline 2022) | Energy efficiency upgrades and fuel switching |
- Innovation: Dedicated R&D centers, clinical partnerships, and pilot manufacturing lines shorten development cycles and support registration for both domestic and export markets.
- Integrity: Governance framework includes independent board oversight, internal audit functions, and expanded regulatory compliance staffing.
- Customer Focus: Enhanced distribution analytics, loyalty programs for institutional clients, and product training for medical representatives improve service levels.
- Sustainability: Capital expenditures prioritized for wastewater treatment upgrades, solvent recovery, and renewable energy pilots at primary sites.
- Collaboration: Joint development agreements with academic institutions and licensing deals to broaden therapeutic coverage and market reach.
- Social Responsibility: Community vaccination drives, drug donation programs, and workplace safety investments form part of ongoing CSR initiatives.
| Governance Area | Mechanism | KPIs Monitored |
|---|---|---|
| R&D Portfolio | R&D Steering Committee | Projects in pipeline, time-to-market, R&D spend / revenue |
| Quality & Compliance | QA/QC Systems + External Audits | Inspection pass rates, recall incidents, CAPA closure time |
| Environmental Management | ISO-aligned EMS and sustainability targets | Emissions, energy use per unit, waste treatment rates |
| Stakeholder Engagement | Annual reporting & investor relations program | Customer satisfaction scores, investor feedback, CSR reach |
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (002675.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.